MYH14 and heart failure: The development of small molecules able to specifically activate or inhibit myosin force production has been successful in several other myosin classes, including the activator omecamtiv mecarbil (OM) and the inhibitor mavacamten (CAMZYOSTM), targeting β-cardiac myosin against heart failure and inherited cardiac diseases13–15 and CK-571, a smooth muscle myosin 2 inhibitor (SmMyo2) against asthma16; reviewed by17–19.